A prospective, randomized, controlled open-label trial to investigate the effects of 10mg rivaroxaban or 110mg dabigatran on microparticle formation in critically ill patients compared to age-& sex-matched subjects

Trial Profile

A prospective, randomized, controlled open-label trial to investigate the effects of 10mg rivaroxaban or 110mg dabigatran on microparticle formation in critically ill patients compared to age-& sex-matched subjects

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 20 Jul 2013

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Rivaroxaban (Primary)
  • Indications Thrombosis
  • Focus Pharmacodynamics
  • Most Recent Events

    • 20 Jul 2013 Status changed from recruiting to discontinued as reported by European Clinical Trials Database record.
    • 07 Oct 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top